Bimekizumab

M. Elaine Husni, MD, MPH, spoke with Healio about treatment and management options in psoriatic arthritis, including lifestyle changes. “We now have really embraced the concept of wellness strategies,” said Husni, vice chair of rheumatology and director of the Arthritis and Musculoskeletal Center and staff physician in the Orthopedic and Rheumatologic Institute at Cleveland Clinic, and assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Healio spoke with Philip J. Mease, MD, about recent advancements in psoriatic arthritis.

The FDA review of the biologics license application for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis has been postponed to the third quarter of 2023, UCB announced in a press release.

UCB announced new long-term data from BE COMPLETE’s 52-week open label extension evaluating the efficacy and safety of bimekizumab in adults with active psoriatic arthritis, according to a press release.

The hidradenitis suppurativa-IGA score strongly correlated with other measures of the condition’s activity and may be more useful for clinicians, according to a study.

The European Medicines Agency has recommended granting marketing authorization for bimekizumab for the treatment of adults with axial spondyloarthritis and active psoriatic arthritis, according to a UCB press release.

The use of bimekizumab to inhibit both interleukin-17A and IL-17F was well-tolerated and impactful in improving axial spondyloarthritis outcomes across two phase 3 trials, according to data published in the Annals of the Rheumatic Diseases.

The FDA has accepted the biologics license application resubmission for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis, according to a UCB release.

Adults with active psoriatic arthritis taking bimekizumab saw significant improvements in joint symptoms and skin clearance compared with those taking placebo, UCB announced in a press release.

Bimekizumab for the treatment of moderate to severe hidradenitis suppurativa met the primary endpoint and key secondary endpoint in two phase 3 studies, UCB announced in a press release.